---
title: 'Targeted multiplex validation of CSF proteomic biomarkers: implications for
  differentiation of PCNSL from tumor-free controls and other brain tumors'
date: '2024-08-15'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39144147/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240816182041&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'INTRODUCTION: Primary central nervous system lymphoma (PCNSL) is a rare
  type of non-Hodgkin''s lymphoma that affects brain parenchyma, eyes, cerebrospinal
  fluid, and spinal cord. Diagnosing PCNSL can be challenging because imaging studies
  often show similar patterns as other brain tumors, and stereotactic brain lesion
  biopsy conformation is invasive and not always possible. This study aimed to validate
  a previous proteomic profiling (PMID: 32610669) of cerebrospinal fluid (CSF) and
  develop ...'
disable_comments: true
---
INTRODUCTION: Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin's lymphoma that affects brain parenchyma, eyes, cerebrospinal fluid, and spinal cord. Diagnosing PCNSL can be challenging because imaging studies often show similar patterns as other brain tumors, and stereotactic brain lesion biopsy conformation is invasive and not always possible. This study aimed to validate a previous proteomic profiling (PMID: 32610669) of cerebrospinal fluid (CSF) and develop ...